Indian pharmaceutical company Zydus Lifesciences reported a 26.6% decline in consolidated net profit for the July–September quarter, as rising operational expenses outweighed strong revenue growth. Net profit dropped to ₹926 crore from ₹1,261 crore in the same period last year. Following the announcement, the company’s shares fell around 4%. Despite the decline in Continue Reading
